Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Granulocyte

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    295 result(s) found for: Granulocyte. Displaying page 1 of 15.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2006-000514-21 Sponsor Protocol Number: AG-PH3 Start Date*: 2007-01-02
    Sponsor Name:CIS bio International
    Full Title: Multicenter, randomized, open-label, clinical study on the agreement of Scintimun® Granulocyte and labeled 99mTc-White Blood Cells in diagnosing infection/inflammation by immunoscintigraphy in peri...
    Medical condition: Patients with suspected or documented osteomyelitis in the peripheral skeleton including patients with loosening of joint prosthesis or diabetic foot. At least one of following signs or symptoms is...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) HU (Completed) DE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2009-010700-28 Sponsor Protocol Number: UniKoeln-478 Start Date*: 2012-03-21
    Sponsor Name:University of Cologne
    Full Title: GRANITE-1 - Granulocyte-transfusions for patients with febrile neutropenia
    Medical condition: Febrile neutropenia due to chemotherapy for the following diseases: C92.0- - Acute myeloid leukemia C91.0- - Acute lymphoblastic leukemia C92.1- - Chronic myeloid leukemia C91.1- - Chronic lymphobl...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10005329 - Blood and lymphatic system disorders 10016288 Febrile neutropenia PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-003537-25 Sponsor Protocol Number: 04032008 Start Date*: 2008-08-28
    Sponsor Name:University Medical Center Groningen
    Full Title: Can the steady-state hematopoiesis be improved post-ASCT by infusion of the autologous stem cell transplant directly in the bone marrow compartment.
    Medical condition: Study population - patient age 18-65 years - eligible for an ASCT for lymphoma or MM - at least ≥ 10 x 106 CD34+ cells/kg have been collected during the previous performed leucofereses procedure
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-004674-27 Sponsor Protocol Number: 14076 Start Date*: 2007-02-14
    Sponsor Name:Dutch Kidney Foundation
    Full Title: Effect of GM-CSF on development of antigen-specific T cell responses following hepatitis B vaccination
    Medical condition: Haemodialysis patients are susceptible for infections due to a continuous mildly activated immune system. About 40% of the haemodialysis patients does not respond to the standard HBV vaccination pr...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10018487 GM-CSF prophylaxis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-005349-39 Sponsor Protocol Number: XM22-02-INT Start Date*: 2008-04-09
    Sponsor Name:BioGeneriX AG
    Full Title: Dose-finding of a fixed dose XM22 in patients with breast cancer receiving 4 cycles of chemotherapy versus 6 mg Neulasta®
    Medical condition: Neutropenia in patients with high risk stage II, stage III or stage IV breast cancer receiving cancer chemotherapy.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-002228-28 Sponsor Protocol Number: STEMALS-II Start Date*: 2014-09-01
    Sponsor Name:Università degli Studi di Torino e Azienda Ospedaliera Città della Salute e della Scienza di Torino
    Full Title: A double blind, placebo controlled, parallel groups, multicenter study on filgrastim in amyotrophic lateral sclerosis
    Medical condition: Amyotrophic lateral sclerosis (ALS) is a severe progressive neurological disorder characterized by a selective degeneration of spinal, bulbar, and cortical motor neurons.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-006301-24 Sponsor Protocol Number: 06/143 Start Date*: 2008-02-21
    Sponsor Name:University College London, Joint Research Office
    Full Title: MULTI CENTRE CONTROLLED STUDY ON THE IMPACT OF STEM CELL DONATION EITHER AFTER MOBILISATION WITH GRANULOCYTE COLONY STIMULATING FACTOR OR BONE MARROW HARVEST ON UNRELATED BONE MARROW DONORS
    Medical condition: Study on the impact of stem cell donation either after mobilisation with granulocyte colony stimulating factor (GCSF) or bone marrow harvest on unrelated donors.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10051716 Peripheral blood stem cell apheresis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-003581-25 Sponsor Protocol Number: APA-III Start Date*: 2015-05-26
    Sponsor Name:University Hospital Tuebingen
    Full Title: Anti-inflammatory pulmonal therapy of CF-patients with Amitriptyline and Placebo - Randomised, double-blind, placebo-controlled cohort trial
    Medical condition: Amitriptyline reduces ceramide concentrations in bronchial epithelial cells and reduces cell death and reduces the deposition of DNA on the respiratory epithelium. This reduction promotes the elimi...
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-001654-21 Sponsor Protocol Number: KKS-279 Start Date*: 2020-09-16
    Sponsor Name:Justus-Liebig-University Gießen
    Full Title: Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Inhalation to prevent ARDS in COVID-19 pneumonia
    Medical condition: COVID-19 pneumonia
    Disease: Version SOC Term Classification Code Term Level
    23.1 10021881 - Infections and infestations 10084380 COVID-19 pneumonia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-001639-38 Sponsor Protocol Number: MDS/2013 Start Date*: 2016-12-06
    Sponsor Name:1st Dep. of Medicine, General University Hospital (VFN) in Prague
    Full Title: Contribution to verify the effectiveness of adding granulocyte stimulating factor (G-CSF) to therapy 5 - Azacitidine patients with the high risk Myelodysplastic syndrome.
    Medical condition: Patients with the diagnosis:HR-MDS, AML less than 30% myeloblasts and CMML II, who will be treated with AZA or AZA + G-CSF.
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-004211-30 Sponsor Protocol Number: 2005-23 Start Date*: 2005-10-17
    Sponsor Name:The Norwegian Radium Hospital
    Full Title: Penicillin G and an aminoglycoside versus meropenem as initial empiric antibiotic therapy in lymphoma and leukemia patients with febrile neutropenia
    Medical condition: Lymphoma and leukemia patients with febrile neutropenia
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-005256-97 Sponsor Protocol Number: SGI-110-06 Start Date*: 2017-06-19
    Sponsor Name:Astex Pharmaceuticals, Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia
    Medical condition: Acute Myeloid Leukemia (AML)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10024291 Leukaemias acute myeloid HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) HU (Completed) ES (Completed) GB (Completed) FR (Completed) PL (Completed) SE (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-005772-16 Sponsor Protocol Number: HEH-SF-01 Start Date*: 2016-06-22
    Sponsor Name:Department of Surgery, Herlev Hospital
    Full Title: The safety and pharmacokinetics of intraperitoneal administration of granulocyte-macrophage colony-stimulating factor, fosfomycin, and metronidazole in patients undergoing appendectomy for uncompli...
    Medical condition: We intend to investigate the safety of treating secondary infectious peritonitis due to uncomplicated appendicitis with intraperitoneally administered fosfomycin, metronidazole and GM-CSF.
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004862 10000677 Acute appendicitis LLT
    19.0 100000004848 10053349 Pharmacokinetic study LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-004498-29 Sponsor Protocol Number: 20190360 Start Date*: 2022-01-13
    Sponsor Name:Amgen Inc.
    Full Title: Phase 3 Randomized, Controlled Study of Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor...
    Medical condition: Newly Diagnosed Philadelphia (Ph)-negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000844 Acute lymphoblastic leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PT (Trial now transitioned) SE (Trial now transitioned) AT (Trial now transitioned) FI (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) DK (Trial now transitioned) IT (Trial now transitioned) BE (Trial now transitioned) HU (Trial now transitioned) BG (Trial now transitioned) NL (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-005034-36 Sponsor Protocol Number: KWI-300-104 Start Date*: 2008-07-15
    Sponsor Name:Apotex Inc.
    Full Title: A non comparative, multicentre, repeat dose safety in use study of Neukine® (Filgrastim) in patients receiving chemotherapy known to induce neutropenia
    Medical condition: Febrile neutropenia in breast cancer patients undergoing TAC chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10016288 Febrile neutropenia LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) AT (Completed) PL (Completed) BG (Completed) GR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-000878-30 Sponsor Protocol Number: 209564 Start Date*: 2020-02-13
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A multi-centre long-term extension study to assess the safety and efficacy of GSK3196165 in the treatment of rheumatoid arthritis.
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    23.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) GB (GB - no longer in EU/EEA) CZ (Prematurely Ended) HU (Prematurely Ended) EE (Completed) DE (Prematurely Ended) LV (Completed) BG (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2008-002195-10 Sponsor Protocol Number: HO89 Start Date*: 2009-05-06
    Sponsor Name:HOVON Foundation
    Full Title: A Phase II randomized multicenter study to assess the efficacy of lenalidomide with or without erythropoietin and granulocyte-colony stimulating factor in patients with low and intermediate-1 risk ...
    Medical condition: myelodysplastic syndrome
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028533 Myelodysplastic syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: View results
    EudraCT Number: 2014-004849-26 Sponsor Protocol Number: Parachute04 Start Date*: 2015-02-05
    Sponsor Name:UMC Utrecht
    Full Title: PARACHUTE-trial Prospective Analysis of an individualized dosing Regimen of ATG (Thymoglobulin) in Children Undergoing HCT: redUcing Toxicity and improving Efficacy – a single arm phase II study
    Medical condition: Leukemia and immunedeficiency syndromes
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10021428 Immune system disorders SOC
    20.1 100000004864 10024329 Leukemia LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2006-003683-54 Sponsor Protocol Number: OSHO #76 Start Date*: 2008-06-18
    Sponsor Name:GMIHO Gesellschaft für medizinische Innovation/Hämatologie und Onkologie mbH
    Full Title: Prospektive, offene, randomisierte, multizentrische Studie zur Effektivität von Palifermin in der Prophylaxe der Mukositis nach allogener Stammzelltransplantation mit myeloablativer Granzkörperbest...
    Medical condition: Patients suffering from leukemia (acute or chronic), receiving allogenic blood stem cell transplantation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-004981-42 Sponsor Protocol Number: GCTSK001 Start Date*: 2008-01-17
    Sponsor Name:Narodny onkologicky ustav
    Full Title: Phase II study of sunitinib malate (SUTENT®) in relapsed germ cell tumors in males.
    Medical condition: germ cell tumor
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: SK (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 18:49:27 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA